Considering the rising demand for biologics, innovators in the biopharmaceutical industry are constantly exploring avenues that would enable them to overcome the existing technical and operational challenges related to viral-clearance and testing for timely approval of biologics. Outsourcing the viral-clearance and viral testing studies has emerged as a promising alternative for most of the manufacturers.
Despite being one of the crucial step amongst all the steps involved in the production of biologics , this service is heavily outsourced in the biopharmaceutical industry. Currently, it is estimated that more than 70% of the these services are employed by biopharmaceutical and pharmaceutical companies
Service providers across the globe offering this service are large players. Of these, close to 80% players provide services for both, viral clearance and viral testing of different type of biologics
Of the players have established their facilities in Europe. Within this region, UK has the maximum number of facilities (over 21%), followed by Germany (more than 15%) and France (close to 10%)
Patents have been filed / granted over last few years. Of these, over 40% patents are granted by organizations headquartered in the US whereas close to 25% patent applications are filed by organizations headquartered in China
As projected by Roots Analysis, more than 55% of the share is captured by viral removal, in the this market
As projected by Roots Analysis, 40% of the share is captured by North America, in this market
Driven by the rising interest in research and development activities and the demand for these clearance and testing services, the future opportunities and growth associated with this market are anticipated to witness a note worthy growth in the foreseen future. Specifically, in terms of end-users, the market is anticipated to be driven by biotechnology and pharmaceutical industry.